title: [Hypertension 2007-2008].
abstract: Hypertension still represents a leading cause of mortality worldwide and a main modifiable risk factor for cardiovascular, cerebrovascular and renal diseases. Therefore, guideline writing groups have proposed new recommendations regarding diagnosis and treatment. Nevertheless, a series of large-scale clinical trials have been published thereafter. Their results, namely the risk associated with the combination of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), the benefits of an initial therapy with a fixed-dose combination of calcium channel blocker and ACE inhibitor, the effectiveness of blood pressure reduction in patients > 80 years, and the introduction of oral renin inhibitors in the market will enormously impact clinical practice.
authors.affiliation: Abteilung für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. chatzikyrkou.christos@mh-hannover.de
authors.forename: Christos
authors.initials: C
authors.lastname: Chatzikyrkou
authors.forename: Jan
authors.initials: J
authors.lastname: Menne
authors.forename: Hermann
authors.initials: H
authors.lastname: Haller
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects; D020521:Stroke / Q000517:prevention & control; D000092502:Renin Inhibitors
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D000092502:Renin Inhibitors